Company Description
F3 Platform Biologics is a late-stage biopharmaceutical company committed to the development and commercialization of novel, practical biotechnology for human use.
We are focused on the research, clinical development, and ultimate commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy.
Amifostine has been shown to repair and protect against human cell mutation and destruction, as well as radiation-induced genomic damage and instability ("RIGDI"), a precursor to carcinogenesis, which occurs when human cells are exposed to low doses of ionizing radiation, such as those present in CT scans.
F3 has developed an amifostine-based opportunity to reduce the incidences of RIGDI and consequential risk of carcinogenesis in CT scan-treated patients.
Our proposed indications of amifostine may not only offer protection against and repair of the harmful effects of RIGDI, they also have the potential to make CT scanning a safer medical practice.
However, our proposed indications are not commercially available or FDA approved yet.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Jonathan E. Peskoff |
Contact Details
Address: 1200 Ashwood Parkway, Ste. 155 Atlanta, GA 30338 United States | |
| Phone | (678) 235-4396 |
| Website | f3pb.com |
Stock Details
| Ticker Symbol | JDRR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001786888 |
| Employer ID | 83-1243304 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jonathan E. Peskoff | Chief Executive Officer |
| James R. Miller | President & Chief Operating Officer |
| Kevin M. Rooney | Chief Business Officer |
| Holger A. Liepmann | Chairman |
| Linda Peters | Director |
| Bernardus N. Machielse | Director |
| Daniel Courchesne | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 20, 2024 | RW | Filing |
| Jun 20, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 8, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 3, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 19, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 8, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jan 12, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Nov 7, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 8, 2022 | DRS | [Cover] Draft Registration Statement |